PhRMA's FIRST POLITICAL OBJECTIVE IS TO GET ITS FDA PROPOSALS INTO REPUBLICAN BILL FOR CONSIDERATION BY HOUSE, WHERE LEGISLATIVE ACTION IS FEASIBLE THIS FALL
The Pharmaceutical Research & Manufacturers of America is meeting with key Republican congressional staff to try to get its legislative proposal for reforming FDA adopted into bills being developed for introduction this summer. The first priority is to get the proposal into a bill in the House, where PhRMA believes a bill could move this fall.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth